- Home
- FFA vs PROK Comparison
FFA vs PROK Comparison
Compare FFA & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFA
- PROK
- Stock Information
- Founded
- FFA 2004
- PROK 2015
- Country
- FFA United States
- PROK United States
- Employees
- FFA N/A
- PROK N/A
- Industry
- FFA Investment Managers
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FFA Finance
- PROK Health Care
- Exchange
- FFA Nasdaq
- PROK Nasdaq
- Market Cap
- FFA 416.1M
- PROK 384.2M
- IPO Year
- FFA N/A
- PROK N/A
- Fundamental
- Price
- FFA $21.00
- PROK $2.37
- Analyst Decision
- FFA
- PROK Buy
- Analyst Count
- FFA 0
- PROK 5
- Target Price
- FFA N/A
- PROK $6.25
- AVG Volume (30 Days)
- FFA 26.1K
- PROK 2.9M
- Earning Date
- FFA 01-01-0001
- PROK 08-12-2025
- Dividend Yield
- FFA 6.72%
- PROK N/A
- EPS Growth
- FFA N/A
- PROK N/A
- EPS
- FFA N/A
- PROK N/A
- Revenue
- FFA N/A
- PROK $527,000.00
- Revenue This Year
- FFA N/A
- PROK $105.79
- Revenue Next Year
- FFA N/A
- PROK N/A
- P/E Ratio
- FFA N/A
- PROK N/A
- Revenue Growth
- FFA N/A
- PROK N/A
- 52 Week Low
- FFA $15.84
- PROK $0.46
- 52 Week High
- FFA $19.30
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- FFA 56.65
- PROK 46.98
- Support Level
- FFA $20.45
- PROK $2.15
- Resistance Level
- FFA $21.24
- PROK $2.59
- Average True Range (ATR)
- FFA 0.19
- PROK 0.33
- MACD
- FFA -0.01
- PROK -0.09
- Stochastic Oscillator
- FFA 61.24
- PROK 19.57
About FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.